Ezetimibe + atorvastatin
Ezetimibe + atorvastatin has been studied in 9 papers since 2017: 6 trials and 1 observational study in people, 2 reviews; 5 in the past year. It is an approved medicine. The newest paper, Nov 2, 2026: “Ezetimibe Plus Atorvastatin versus Double-Dose Atorvastatin Monotherapy for Hypercholesterolemia: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials”.
9 papers study it24 more mention it20 findingsUpdated
10 new papers in 30 daysSee all 33 papers on ezetimibe + atorvastatin
At a glance
Independent labs found the same change in people. 7 independent labs in 4 countries; 116 trials, 61 about aging, 60 with no results posted.
“AS/EZ FDC reduced LDL-C more than AS alone (MD -13.94%, 95% CI [-18.90% to -9.10%])”
None of its findings points the other way.
- 7 independent labs in 4 countries
- 116 trials, 61 about aging, 60 with no results posted
- Funder: Organon
- 6 of 20 findings with company ties
- 1 of 116 trials sponsored by its developers
- Human trial6
- Humans1
Studies in people
See all 7 studies of ezetimibe + atorvastatin in people7 studies gave ezetimibe + atorvastatin to people and measured what changed.
| What changed | Design | People | Source |
|---|---|---|---|
down: Decreases LDL-CMD -13.94%, 95% CI -18.90% to -9.10% vs atorvastatin alone up: Increases LDL-C goal attainmentRR 1.87 (95% CI 1.47-2.39) no change: Has no effect on adverse events | Review of trials | 10,567 people pooledPatient cohorts | PeerJ, Oct 21, 2026 |
down: Decreases LDL-CLDL-C reduction 45.15% vs 29.43% with atorvastatin alone at 4 weeks up: Increases LDL-C goal attainment no change: Has no effect on adverse events | Randomized trial4 weeks | 254 peoplePatient cohorts | The Journal of the Association of Physicians of India, Mar 1, 2026 |
down: Decreases LDL-CWeek 6 LSMD: -21.2; P < 0.0001; week 12 LSMD: -16.0; P < 0.0001 no change: Has no effect on adverse event incidence | Randomized trial6 weeks | 137 people≥ 30 yearsVery high-risk ASCVD | BMC cardiovascular disorders, Feb 11, 2026 |
up: Increases LDL-C goal attainment62.7% vs. 35.1%, P = 0.0009 | Randomized trial12 weeks | BothOlder adults; cohort A | Advances in therapy, Jan 19, 2026 |
down: Decreases low-density lipoprotein cholesterolLSMD -21.22 (95% CI -29.26 to -13.19) at week 6 vs atorvastatin up: Increases LDL-C goal achievement46.2% vs 9.0% at week 6; 55.0% vs 15.4% at week 12 no change: Has no effect on safety profile | Randomized trial6 weeks | 137 peoplemean 65.0 (SD 10.35) yearsPatient cohorts | AHA Scientific Sessions 2025 abstract, Nov 3, 2025 |
What did studies of ezetimibe + atorvastatin find?
15Studies of ezetimibe + atorvastatin measured 15 outcomes, among them adverse events, LDL-C and LDL-C goal attainment.
Adverse events
no changein humans3
3 studies
Adverse events
no changein humans3
Ezetimibe + atorvastatin showed no clear effect on adverse events in humans (compared with atorvastatin monotherapy).
“Treatment with AS/EZ FEC or FDC did not increase the risk of adverse events compared to AS monotherapy and was well tolerated.”
Human trialcompared with atorvastatin monotherapy
PeerJ
Ezetimibe + atorvastatin showed no clear effect on adverse events in humans (compared with atorvastatin alone).
“Adverse events were similar in both groups.”
Human trialcompared with atorvastatin aloneatorvastatin 80 mg plus ezetimibe 10 mg once daily
The Journal of the Association of Physicians of India
Ezetimibe + atorvastatin showed no clear effect on adverse events in humans (hypercholesterolemia; compared with double-dose atorvastatin) (18.2% versus 17.5%; p=0.56).
“Safety outcomes were similar (18.2% vs. 17.5% adverse events; p=0.56).”
Reviewhypercholesterolemia; compared with double-dose atorvastatinezetimibe 10 mg plus atorvastatin at half the comparator dose56% malesn = 5,924
AHA Scientific Sessions 2026 abstract
LDL-C
downin humans3
3 studies
LDL-C
downin humans3
Ezetimibe + atorvastatin decreases LDL-C in humans (versus atorvastatin monotherapy) (MD -13.94%, 95% CI -18.90% to -9.10% vs atorvastatin alone).
“AS/EZ FDC reduced LDL-C more than AS alone (MD -13.94%, 95% CI [-18.90% to -9.10%])”
Human trialversus atorvastatin monotherapyfixed-dose combination
PeerJ
Ezetimibe + atorvastatin decreases LDL-C in humans (compared with atorvastatin alone) (LDL-C reduction 45.15% vs 29.43% with atorvastatin alone at 4 weeks).
“29.43% in group A vs 45.15% in group B at 4 weeks (p < 0.001)”
Human trialcompared with atorvastatin aloneatorvastatin 80 mg plus ezetimibe 10 mg once daily4 weeks
The Journal of the Association of Physicians of India
Ezetimibe + atorvastatin decreases LDL-C in humans (Very high-risk ASCVD; compared with atorvastatin 40 mg monotherapy) (Week 6 LSMD: -21.2; P < 0.0001; week 12 LSMD: -16.0; P < 0.0001).
“The EZ/AS lipid-lowering effect was statistically greater than AS monotherapy at week 6 (LSMD: -21.2; P < 0.0001) and week 12 (LSMD: -16.0; P < 0.0001).”
Human trialVery high-risk ASCVD; compared with atorvastatin 40 mg monotherapyezetimibe 10 mg + atorvastatin 40 mg once daily6 weeksn = 137
BMC cardiovascular disorders
LDL-C goal attainment
upin humans2RR 1.87
2 studies
LDL-C goal attainment
upin humans2RR 1.87
Ezetimibe + atorvastatin increases LDL-C goal attainment in humans (free-equivalent combination vs atorvastatin monotherapy) (RR 1.87 (95% CI 1.47-2.39)).
“For LDL-C goal attainment, the RR was 1.87 (95% CI [1.47-2.39]) for FEC vs. monotherapy”
Human trialfree-equivalent combination vs atorvastatin monotherapyfree-equivalent combination
PeerJ
Ezetimibe + atorvastatin increases LDL-C goal attainment in humans (compared with atorvastatin alone).
“with a markedly higher proportion of participants achieving LDL-C goals at 4 and 12 weeks”
Human trialcompared with atorvastatin aloneatorvastatin 80 mg plus ezetimibe 10 mg once daily4 and 12 weeks
The Journal of the Association of Physicians of India
LDL cholesterol
downin humans1
1 study
LDL cholesterol
downin humans1
Ezetimibe + atorvastatin decreases LDL cholesterol in humans (hypercholesterolemia; compared with double-dose atorvastatin) (-14.6% versus double-dose atorvastatin).
“At 8 weeks, combination therapy reduced LDL-C more (-14.6%; p<0.001; I 2 =28%).”
Reviewhypercholesterolemia; compared with double-dose atorvastatinezetimibe 10 mg plus atorvastatin at half the comparator dose8 weeks56% malesn = 5,924
AHA Scientific Sessions 2026 abstract
Adverse event incidence
no changein humans1
1 study
Adverse event incidence
no changein humans1
Ezetimibe + atorvastatin showed no clear effect on adverse event incidence in humans (Very high-risk ASCVD; compared with atorvastatin 40 mg monotherapy).
“Incidence of adverse events were comparable between EZ/AS and AS groups.”
Human trialVery high-risk ASCVD; compared with atorvastatin 40 mg monotherapyezetimibe 10 mg + atorvastatin 40 mg once daily12 weeksn = 137
BMC cardiovascular disorders
LDL-C goal attainment
upin humans1
1 study
LDL-C goal attainment
upin humans1
Ezetimibe + atorvastatin increases LDL-C goal attainment in humans (cohort A) (62.7% vs. 35.1%, P = 0.0009).
“LDL-C goal attainment was significantly higher with FDCs versus AS monotherapy at week 12 (cohort A: 62.7% vs. 35.1%, P = 0.0009; cohort B: 67.5% vs. 31.0%, P < 0.0001).”
Human trialcohort A12 weeks
Advances in therapy
Safety profile
no changein humans1
1 study
Safety profile
no changein humans1
Ezetimibe + atorvastatin showed no clear effect on safety profile in humans (compared with atorvastatin monotherapy at weeks 6 and 12).
“The safety profile was comparable between the groups at week 6 and week 12.”
Human trialcompared with atorvastatin monotherapy at weeks 6 and 1210/40 mg10/40 mg12 weeksn = 137
AHA Scientific Sessions 2025 abstract
LDL-C goal achievement
upin humans1
1 study
LDL-C goal achievement
upin humans1
Ezetimibe + atorvastatin increases LDL-C goal achievement in humans (compared with atorvastatin monotherapy at week 6) (46.2% vs 9.0% at week 6; 55.0% vs 15.4% at week 12).
“Significantly higher proportions of patients achieved target LDL-C levels <55 mg/dL in EZ/AS group compared with AS group at week 6 (46.2% vs. 9.0%; P <0.0001)”
Human trialcompared with atorvastatin monotherapy at week 610/40 mg10/40 mg6 weeksn = 137
AHA Scientific Sessions 2025 abstract
Low-density lipoprotein cholesterol
downin humans1
1 study
Low-density lipoprotein cholesterol
downin humans1
Ezetimibe + atorvastatin decreases low-density lipoprotein cholesterol in humans (compared with atorvastatin monotherapy at week 6) (LSMD -21.22 (95% CI -29.26 to -13.19) at week 6 vs atorvastatin).
“Lipid-lowering efficacy was significantly greater with EZ/AS compared with AS monotherapy at Week 6 (LS mean difference [LSMD]: -21.22; 95% CI: -29.26, -13.19; P <0.0001)”
Human trialcompared with atorvastatin monotherapy at week 610/40 mg10/40 mg6 weeksn = 137
AHA Scientific Sessions 2025 abstract
Total bilirubin
upin humans1
1 study
Total bilirubin
upin humans1
Ezetimibe + atorvastatin increases total bilirubin in humans.
“Total bilirubin, DBIL, and IBIL were higher in the combined group than in the control group (P < .05).”
Human trialin elderly patients with hypertension and type 2 diabetes mellitus, versus atorvastatin alonen = 112
Alternative therapies in health and medicine
Inflammatory factors
downin humans1
1 study
Inflammatory factors
downin humans1
Ezetimibe + atorvastatin decreases inflammatory factors in humans.
“Glucose, lipid function, and inflammatory factors were lower in the combined group than in the control group (P < .05).”
Human trialin elderly patients with hypertension and type 2 diabetes mellitus, versus atorvastatin alonen = 112
Alternative therapies in health and medicine
Lipid function
downin humans1
1 study
Lipid function
downin humans1
Ezetimibe + atorvastatin decreases lipid function in humans.
“Glucose, lipid function, and inflammatory factors were lower in the combined group than in the control group (P < .05).”
Human trialin elderly patients with hypertension and type 2 diabetes mellitus, versus atorvastatin alonen = 112
Alternative therapies in health and medicine
Blood glucose
downin humans1
1 study
Blood glucose
downin humans1
Ezetimibe + atorvastatin decreases blood glucose in humans.
“Glucose, lipid function, and inflammatory factors were lower in the combined group than in the control group (P < .05).”
Human trialin elderly patients with hypertension and type 2 diabetes mellitus, versus atorvastatin alonen = 112
Alternative therapies in health and medicine
Alanine aminotransferase elevation
downin humans1
1 study
Alanine aminotransferase elevation
downin humans1
Ezetimibe + atorvastatin decreases alanine aminotransferase elevation in humans (versus double-dose atorvastatin 20 mg/d) (2.8% vs. 9.0%).
“The patients whose alanine aminotransferase increasing more than upper normal limit in combined group was lower than double-dose atorvastatin group (2.8% vs. 9.0%, p = 0.05).”
Human trialversus double-dose atorvastatin 20 mg/datorvastatin 10 mg + ezetimibe 10 mg vs atorvastatin 20 mg
Oncotarget
Major adverse cardiovascular events
no changein humans1HR 1.12
1 study
Major adverse cardiovascular events
no changein humans1HR 1.12
Ezetimibe + atorvastatin showed no clear effect on major adverse cardiovascular events in humans (Cox regression versus double-dose atorvastatin 20 mg/d) (HR 1.12 (95% CI 0.51–2.55)).
“the risk of major adverse cardiovascular events in combined group isn't significantly higher than double-dose atorvastatin group (HR [95% CI] 1.12 [0.51 to 2.55], p = 0.74)”
Human trialCox regression versus double-dose atorvastatin 20 mg/datorvastatin 10 mg + ezetimibe 10 mg vs atorvastatin 20 mgone year
Oncotarget
Has ezetimibe + atorvastatin been tested in people?
61 of 116 about agingYes: 6 trials and 1 observational study in people have been published, and 58 trials are registered.
About aging
A Clinical Trial of STAtin Therapy for Reducing Events in the Elderly (STAREE)
Phase 4Active, not recruiting
Statins in Reducing Events in the Elderly Mind (STAREE-Mind) Imaging Substudy
Phase 4Active, not recruiting
Phase 4Completed
Lipitor In The Prevention Of Stroke, For Patients Who Have Had A Previous Stroke
Phase 4Completed
Phase 3Completed
Lipitor Phase 4 Clinical Trial in Hypercholesteremia Patients With Yellow Coronary Plaque
Phase 4Completed
All 40Fewer
Approved
May 3, 2013Discontinued
Every condition in trials
Phase 4Results posted28 trials
Phase 4Results posted6 trials
Phase 4Completed4 trials
Phase 4Completed3 trials
Phase 4Completed2 trials
Phase 4Completed2 trials
All 28Fewer
Readouts due
- Jul 1, 2027
Cholesterol Lowering and Residual Risk in Diabetes, Type 1
Phase 4Recruiting
- Nov 12, 2027
Who is developing ezetimibe + atorvastatin?
2 companies: Organon and Daiichi Sankyo.
Trial sponsors
Company23 trialsPhase 48,875 people
Company1 trialPhase 4300 people
Company3 trialsPhase 31,169 people
Company3 trialsPhase 3219 people
Company2 trialsPhase 3192 people
Company2 trialsPhase 3180 people
Company1 trialPhase 31,784 people
Company1 trialPhase 3511 people